Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276120 · ClinicalTrials.gov registry record
Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 4,385
- Enrollment target
NCT00276120: Completed study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT00276120 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 4,385 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00276120 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 4,385 participants
- Enrollment target
Study Summary
The purpose of this study is to identify novel genetic factors which distinguish breast cancer in younger women compared to older women. By identifying these novel genetic factors we believe more specific therapies can be developed and breast cancer may be prevented among women with an increased cancer risk. A woman does not have to live in St. Louis to participate.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,385 participants |
| Start Date | 2005-03 |
| Est. Completion | 2021-12-31 |
What the finished NCT00276120 record still lists
NCT00276120 is an observational study that tracks outcomes without assigning an intervention. Its 4,385 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00276120 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00276120 about?
NCT00276120 is a clinical study titled "Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer". The purpose of this study is to identify novel genetic factors which distinguish breast cancer in younger women compared to older women. By identifying these novel genetic factors we believe more specific therapies can be developed and breast cancer may be prevented among women with an increased can...
What is the current status of trial NCT00276120?
This trial is currently completed. The enrollment target is 4,385 participants. The study started on 2005-03. Estimated completion is 2021-12-31.
Who is sponsoring clinical trial NCT00276120?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07044297 · 4,390 participants · Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
- NCT02660645 · 4,400 participants
Blue Light Cystoscopy With Cysview® Registry
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia